International Journal of Clinical Pharmacy

, Volume 34, Issue 6, pp 822–824 | Cite as

Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent

  • Maryam Karimi Khaledi
  • Katie J. SudaEmail author
  • Chasity M. Shelton
Case Report


Case The objective of this case report is to report the development of tardive dyskinesia in an African-American adolescent male after short-term treatment with metoclopramide 10 mg orally three times daily secondary to delayed gastric emptying. The patient developed symptoms of tardive dyskinesia after 2 days of therapy with metoclopramide. Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed. While there are case reports of drug-induced tardive dyskinesia after intravenous administration of metoclopramide, this is to our knowledge the first report of tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. Conclusion Awareness of the risk of development of this adverse effect even with short-term treatment with metoclopramide and in younger patients is important.


Drug toxicity Metoclopramide Movement disorders Tardive dyskinesia 




Conflicts of interest

The authors have no conflicts of interest or financial disclosures to report.


  1. 1.
    Food and Drug Administration. FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs [internet] (2009) [cited 2012 Jan 29]. Available from:
  2. 2.
    Gardos G, Casey DE, Cole JO, Pereny A, Kocsis E, Arato M, et al. Ten year outcome of tardive dyskinesia. Am J Psychiatry. 1994;151:836–41.PubMedGoogle Scholar
  3. 3.
    Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521–8.PubMedGoogle Scholar
  4. 4.
    Grimes JD, Hassan MN, Preston DN. Adverse neurologic effects of metoclopramide. Can Med Assoc J. 1982;126:23–5.PubMedGoogle Scholar
  5. 5.
    Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, et al. The Mount Sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull. 2002;28:5–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of literature. Arch Inter Med. 1989;149:2486–92.CrossRefGoogle Scholar
  8. 8.
    Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRefGoogle Scholar
  10. 10.
    Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20:86–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Putnam PE, Orenstien SR, Wessel HB, Stowe RM. Tardive dyskinesia associated with the use of metoclopramide in a child. J Pediatr. 1992;121:983–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48:379–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Maryam Karimi Khaledi
    • 1
  • Katie J. Suda
    • 1
    Email author
  • Chasity M. Shelton
    • 2
  1. 1.Department of Clinical PharmacyUniversity of Tennessee Health Science CenterMemphisUSA
  2. 2.Department of Clinical PharmacyUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations